引用本文:
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 次   下载 本文二维码信息
码上扫一扫!
分享到: 微信 更多
短期胰岛素泵强化治疗对初诊2型糖尿病患者预后及胰岛β细胞功能的影响
邢倩,白然,蒋召芹,王爽,王咏波
大连医科大学 附属第一医院 内分泌科,辽宁 大连 116011
摘要:
[目的] 观察经2周短期应用胰岛素泵治疗的初诊2型糖尿病(T2DM)1年后的血糖控制情况、胰岛β细胞功能及胰岛素敏感性变化。[方法] 初诊2型糖尿病患者32例经持续皮下胰岛素输注(CSII)强化治疗2~4周后,继之分别以胰岛素、口服降糖药(OHA)、单纯生活方式控制血糖,观察1年后的血糖控制情况、胰岛β细胞功能及胰岛素敏感性的差别。[结果] CSII治疗2周期间胰岛素用量差异有显著性意义(P<0.05);3组治疗后1年的FPG、2hPBG、HbA1c、FCP、2hCP、HOMA-β、HOMA-IR平均值各组间比较,差异无显著性意义(P>0.05);1年后转归为:18例(56.25%)仅予生活方式干预;14例(43.75%)予OHA,无1例应用胰岛素。[结论] 对伴有明显高血糖的初诊T2DM患者应用短期CSII治疗,1年后不需再用胰岛素治疗,且多数患者不需应用任何降糖药物,仍可获得满意血糖控制,胰岛β细胞功能得到恢复。
关键词:  2型糖尿病  胰岛素  强化治疗
DOI:10.11724/jdmu.2012.03.16
分类号:
基金项目:
Prognosis and islet β cell function in newly diagnosed type 2 diabetic patients treated with short-term subcutaneous insulin infusion
XING Qian, BAI Ran, JIANG Zhao-qin, WANG Shuang, WANG Yong-bo
Department of Endocrinology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
Abstract:
[Objective] To investigate the long-term (1 year) efficacy and effects on beta-cell function and insulin sensitivity in newly diagnosed type 2 diabetic patients treated with short-term continuous subcutaneous intensive insulin therapy. [Methods] A total of thirty-two newly diagnosed type 2 diabetic patients with fasting plasma glucose (FPG) ≥11.1 mmol/L, glycoslated hemoglobin (HbA1c) ≥ 9% were enrolled. After two weeks intensive therapy of continuous subcutaneous insulin infusion and one year later, body mass index (BMI), FPG, HbA1c and 2 hour postprandial blood glucose (2hPBG), fasting C peptide (FCP) and 2 hours C peptide (2hCP) after seventy-five grams oral glucose load were recorded. Homeostasis model assessment-insulin resistance (HOMA-IR) and homeostasis model assessment-pancreatic beta-cell (HOMA-β) were calculated to evaluate insulin resistance. [Results] One year later, there is no statistical difference in the mean values of FPG and 2hPBG after 2 weeks CSII therapy. HbA1c and HOMA-IR were significantly decreased compared with those at baseline (P<0.05). FCP, 2hCP and HOMA-β after treatment were significantly higher than those at baseline (P<0.05). One year later, 56.25% patients may keep good glycemic control only rely on diet and exercise, without any agent. No patient used insulin. [Conclusion] For newly diagnosed T2DM patients with high blood glucose, short-term CSII treatment can effectively induce good glycemic control even one-year later, and significantly improve beta-cell function and insulin sensitivity. Most patients have good glycemic control without any agents or insulin.
Key words:  T2DM  insulin  intensive therapy